Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

14
Goldman Sachs (GS) Q2 Earnings Impress on Record Revenues

8m zacks
Reflecting the highest strong second-quarter net revenues in nine years, Goldman Sachs’ (GS - Free Report) second-quarter 2018 results recorded a positive earnings surprise of 28.1%. The company reported earnings per share of $5.98, comfortably beating the Zacks Consensus Estimate of $4.67. Further, the bottom line witnessed 51.4% year-over-year improvement. The investment bank turned triumphant with strong Fixed Income, Currency and Commodities (FICC) Client Execution revenues, and a continued momentum in investment banking business, supporting the bottom-line numbers.
WFCNP HD GS.PRB WFC.PRL GS.PRA WFC.PRJ USB WFC.PRT GS WFC.PRR GLSSP WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS JBK C GSC GS.PRICL TFG GSJ GS.PRJ GS.PRI GS.PRD GS.PRC GJS GS.PRN GS.PRK

10
Oil's double slump shows market roiled by week of bearish news

1h worldoil
Since the middle of last week, Brent crude had two of its largest single-day dollar declines in years. The cause of the rout: expanding supplies from nations where there had been major outages -- such as Libya -- at a time of mounting concerns about demand as a trade war between the U.S. and China escalates. As if that weren’t enough, signals from the physical cargo-trading market are suddenly looking weaker too.
C.WSA GS.PRB GS.PRA GS C.WS.B GLSSP C.WS.A C.PRP C.PRU C.PRS JBK C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI C.PRPCL GS.PRD CGBBW GS.PRC GJS GS.PRN GS.PRK

5
Citigroup: Going Higher

3h seekingalpha
While the name is improving in several key metrics, the overall performance leaves something to be desired especially compared to peers.
C

23
5 Strong Earnings Stocks to Buy Post-Netflix Plunge | InvestorPlace

4h investorplace
Netflix, Inc. (NASDAQ:NFLX) may be plunging 14% right now. But don’t let that faze you. There is a reason why the Street has always been cautious about investing in Netflix. Even now I can see that top analysts only have a cautiously optimistic Buy rating on NFLX. And post-plunge they are still only modelling for 4% upside potential from current levels. Netflix is still expensive full stop.
WFCNP FB C.WSA WFC.PRL NFLX WFC.PRJ GOOG WFC.PRT C.WS.B ZION WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC VFC WFC.WS C C.PRL C.PRJ C.PRK NYTAB C.PRG C.PRC JPM GOOGL C.PRPCL CGBBW PNC RTN

9
Comerica (CMA) Q2 Earnings Improve Y/Y, Revenues Increase

4h zacks
Comerica (CMA - Free Report) reported adjusted earnings per share of $1.90 in second-quarter 2018, up from the year-ago adjusted figure of $1.15. Including certain non-recurring items, earnings came in at $1.87. The Zacks Consensus Estimate was $1.62.
WFC WFCNP WFC.WS C CMA WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY 3772 WFC.PRX WFC.PRW WFC.PRV

10
Goldman Sachs beats on bond trading strength, names new CEO

5h theedgemarkets
BENGALURU (July 17): Goldman Sachs Group Inc reported a better-than-expected quarterly profit on Tuesday and named bank insider David Solomon to replace long-time Chief Executive Lloyd Blankfein.
C.WSA GS.PRB GS.PRA GS C.WS.B GLSSP C.WS.A C.PRP C.PRU C.PRS JBK C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI C.PRPCL GS.PRD CGBBW GS.PRC GJS GS.PRN GS.PRK

5
C / Citigroup, Inc. FWP

6h sec.gov
FWP FILED PURSUANT TO RULE 433 File No. 333-224495
C

10
Goldman Sachs beats on bond trading strength, names new CEO - Channel NewsAsia

6h channelnewsasia
Goldman Sachs Group Inc reported a 44 percent rise in second-quarter profit on Tuesday, driven by strength in its investment banking and fixed income trading businesses.
C.WSA GS.PRB GS.PRA GS C.WS.B GLSSP C.WS.A C.PRP C.PRU C.PRS JBK C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI C.PRPCL GS.PRD CGBBW GS.PRC GJS GS.PRN GS.PRK

92
5
C / Citigroup, Inc. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

9h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supplement, prospectus supplement and prospe
C

5
C / Citigroup, Inc. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

9h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supplement, prospectus supplement and prospe
C

82
My Top 5 Undervalued DGI Stocks

9h seekingalpha
On Saturday afternoon I was watching Regis “Rougarou” Prograis fight on ESPN. If you’re a boxing fan, you’ve got to take a look at this heavy fisted southpaw. He’s got the entire city of New Orleans behind him and he brings a ton of energy to the ring. The kid is tenacious and I think he has the mark of a true champion.
IBM BAC GEC GE C GILD CMCSA TWX NFLX CA TWC BAC JNJ AVGO GNE

9
Not even a strong earnings season will break stocks out of their range, Morgan Stanley says - MarketWatch

16h marketwatch
The second-quarter earnings season just started in the U.S., and while the initial reads have shown strong growth for both profits and revenue, such results may not be enough to power the market out of the range it has been stuck in for months.
WFCNP C.WSA MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C C.PRL C.PRJ C.PRK C.PRG C.PRC MS.PRI C.PRPCL MS.PRK CGBBW

9
Charles Schwab (SCHW) Climbs 0.9% Ahead of Earnings: What To Watch

19h zacks
Shares of Charles Schwab (SCHW - Free Report) popped nearly 1% during regular trading hours Monday, just one day before the financial services firm is set to release its latest quarterly financial results. Let’s see what investors should expect.
WFC SCHW.PRBCL WFCNP WFC.WS C WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

13
U.S. banks depositors shifting money, asking for higher rates

21h reuters
NEW YORK, July 16 (Reuters) - Slowly but surely, depositors are starting to shift money from basic U.S. bank accounts to products that pay more than a sliver of a percent in interest.
WFCNP C.WSA WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C C.PRL PNC.PRP C.PRJ PNC.PRQ C.PRK PNCFO C.PRG C.PRC PNC.WS C.PRPCL CGBBW PNC PNUCL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

14h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

15h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to C / Citigroup, Inc. on message board site Silicon Investor.

Canu0027t Beat Amazon! The Trump Presidency
Da_cheifs vomitorium Qualcomm Moderated Thread - please read rules before posting
Immunomedics (IMMU) - moderated Buy and Sell Signals, and Other Market Perspectives
Politics for Pros- moderated Formerly About Advanced Micro Devices
A Real American President: Donald Trump View from the Center and Left
CUSIP: 172967424